Drug Trial Radar · NCT06680531
A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 31, 2024
Primary completion
Sep 19, 2024
Study completion Nov 4, 2024
Sponsor
- Lead sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: 1\) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; To observe the safety of YZJ-1139 tablets taken together with Escitalopram oxalate tablets.
Conditions
- Insomnia
- Central Nervous System
Interventions
YZJ-1139 tabletsDrug
YZJ-1139 tablets are administered orally single dose
Escitalopram oxalate tabletsDrug
•oral tablet, QD
YZJ-1139 simulated tabletsDrug
oral tablet, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- saccade eye movement testTime frame: From Day 1 to Day 11
- body swing testTime frame: From Day 1 to Day 11
- selective reaction time testTime frame: From Day 1 to Day 11
- number symbol conversion testTime frame: From Day 1 to Day 11
- word memory testTime frame: From Day 1 to Day 11
- Maximum Observed Plasma Concentration (Cmax) of YZJ-1139Time frame: From Day 1 to Day 11
- Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of YZJ-1139Time frame: From Day 1 to Day 11
- Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of YZJ-1139Time frame: From Day 1 to Day 11
- Time of Maximum Observed Plasma Concentration (Tmax) of EntrectinibTime frame: From Day 1 to Day 11
- Apparent Terminal Elimination Half-life (t1/2) of EntrectinibTime frame: From Day 1 to Day 11
- Apparent Oral Clearance (CL/F) of EntrectinibTime frame: From Day 1 to Day 11
- The Apparent Volume of Distribution (Vz/F) of EntrectinibTime frame: From Day 1 to Day 11
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.